Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further ...

AbbVie stock (NYSE: ABBV) experienced a 5% decline yesterday, and the reason is evident: the U.S. FDA has just approved Johnson & Johnson’s Icotyde, the first oral IL-23 inhibitor on the market. This ...

Spyre Therapeutics, Inc. earns a Strong Buy on Phase 1 wins, IBD/RA pipeline catalysts, and $757M cash runway. Click for this ...

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced that it has regained compliance with ...

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact ...

This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.

Based on current projections, Incannex believes the proceeds from the offering will be sufficient to complete the DReAMzz Phase 2 study for IHL-42X. The Company’s current cash on hand, prior to ...

ARK Invest purchased ~281K CRISPR Therapeutics (CRSP) shares worth $14.82M after a 10% drop triggered by a $350M private offering announcement.

Dividend Kings are a great way for investors to generate passive income or grow their portfolios even faster through dividend reinvestment. These are my top five Dividend Kings to buy in March 2026.

About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...

The S&P 500 declined 2% during the first week of March after the U.S. and Israel launched attacks on Iran. Brent crude oil recently hit $94 per barrel, the highest price since late 2022, as Iran has ...